Medtronic's Hugo Surgical Robot Wins Regulatory Nod In Europe - Medtronic (NYSE:MDT)

Medtronic plc MDT has secured European approval for its Hugo surgical robot.
Hugo performed its first human procedure in June this year, a minimally invasive prostatectomy in Chile.
It has since expanded to Latin America, with a series of initial gynecological surgeries completed in Panama.
The robotic platform, made up of modular surgical arms on wheeled carts, has also checked off its first operation in the Asia-Pacific region through a prostatectomy in India.
The Company's systems are linked to a global patient registry, which tracks outcomes and feeds that data back into the platform.
The CE mark covers urologic and gynecologic procedures, such as hysterectomies and the removal of uterine fibroids.
The Hugo system is designed to provide a lower barrier to entry for hospitals looking to expand their reach in robotic surgery.
Related: Medtronic Expands Recall of MiniMed 600 Series Insulin Pumps.
Price Action: MDT shares are down 0.40% at $124.77 during the market session on the last check Monday.